Literature DB >> 21737998

Assessment of body fat composition disturbances by bioimpedance analysis in HIV-infected adults.

P Freitas1, D Carvalho, A C Santos, J Mesquita, F Correia, S Xerinda, R Marques, E Martinez, A Sarmento, J L Medina.   

Abstract

HIV-lipodystrophy syndrome is characterized by different patterns of body fat distribution (BFD) which are identified by clinical and body composition (BC) assessment, including bioimpedance analysis (BIA). Our aim was to compare BC in HIV-infected patients on combination antiretroviral therapy (cART) according to 4 distinct phenotypes of BFD (G1-no lipodystrophy, G2-isolated central fat accumulation, G3-lipoatrophy, G4-mixed forms of lipodystrophy) and assessed factors associated with them. Anthropometry and BIA were performed in 344 HIV-1 patients. G2 and G4 phenotype patients had significantly higher fat mass (FM) but no differences were observed in fat-free mass (FFM) and total body water among the 4 phenotypes. Significant negative associations were found between the presence of lipoatrophy and female gender, body mass index (BMI), waist (WC), hip (HC) and thigh circumferences, and total body FM estimated by BIA. After adjustment for gender, cART duration and BMI, G3 had significant lower WC [odds ratio (OR)=0.84; 0.78- 0.90] and HC (OR=0.88; 0.81-0.96) mean. Independently of gender, cART duration and BMI, G2 remained significantly associated with higher WC (OR=1.11; 1.05-1.18) and HC (OR=1.15; 1.07-1.23) mean, and with FM estimated by BIA [FM as %, OR=1.17 (1.09-1.26); and FM as kg, OR=1.15 (1.06- 1.25)]. There was a significant positive association between G4 and female gender (OR=1.66; 1.01-2.75), BMI (OR=1.10; 1.04-1.17) and WC (OR=1.15; 1.09-1.21). The similar FFM along the BFD spectrum describes the actual BC of these patients without sarcopenia. In a clinical setting, BIA is an easy and useful tool to evaluate fat mass and FFM and gives us a picture of BC that was not possible with anthropometry.

Entities:  

Mesh:

Year:  2011        PMID: 21737998     DOI: 10.3275/7841

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  41 in total

Review 1.  Clinical perspectives on HIV-associated lipodystrophy syndrome: an update.

Authors:  A Shevitz; C A Wanke; J Falutz; D P Kotler
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

2.  Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use.

Authors:  C Hadigan; C Corcoran; T Stanley; S Piecuch; A Klibanski; S Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

3.  Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.

Authors:  E L Murphy; A C Collier; L A Kalish; S F Assmann; M F Para; T P Flanigan; P N Kumar; L Mintz; F R Wallach; G J Nemo
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

Review 4.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Authors:  A Carr; K Samaras; D J Chisholm; D A Cooper
Journal:  Lancet       Date:  1998-06-20       Impact factor: 79.321

5.  Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy.

Authors:  H R Brodt; B S Kamps; P Gute; B Knupp; S Staszewski; E B Helm
Journal:  AIDS       Date:  1997-11-15       Impact factor: 4.177

6.  Clinical assessment of HIV-associated lipodystrophy in an ambulatory population.

Authors:  K A Lichtenstein; D J Ward; A C Moorman; K M Delaney; B Young; F J Palella; P H Rhodes; K C Wood; S D Holmberg
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

7.  Regional body fat distribution in HIV-infected patients with lipodystrophy.

Authors:  Warren L Dinges; Dali Chen; Peter G Snell; Paul T Weatherall; Dolores M Peterson; Abhimanyu Garg
Journal:  J Investig Med       Date:  2005-01       Impact factor: 2.895

8.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

9.  Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients.

Authors:  Kenneth A Lichtenstein; Kathleen M Delaney; Carl Armon; Douglas J Ward; Anne C Moorman; Kathleen C Wood; Scott D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2003-01-01       Impact factor: 3.731

10.  Early changes of body composition in human immunodeficiency virus-infected patients: tetrapolar body impedance analysis indicates significant malnutrition.

Authors:  M Ott; B Lembcke; H Fischer; R Jäger; H Polat; H Geier; M Rech; S Staszeswki; E B Helm; W F Caspary
Journal:  Am J Clin Nutr       Date:  1993-01       Impact factor: 7.045

View more
  9 in total

1.  IL-4 and IL-6 levels and adipose tissue distribution in HIV-1 patients under antiretroviral therapy.

Authors:  S Belo; A C Santos; A Madureira; J Pereira; A Sarmento; D Carvalho; P Freitas
Journal:  J Endocrinol Invest       Date:  2015-02-27       Impact factor: 4.256

2.  Carotid intima media thickness is associated with body fat abnormalities in HIV-infected patients.

Authors:  Paula Freitas; Davide Carvalho; Ana Cristina Santos; António José Madureira; Esteban Martinez; Jorge Pereira; António Sarmento; José Luís Medina
Journal:  BMC Infect Dis       Date:  2014-06-23       Impact factor: 3.090

3.  Adipokines, hormones related to body composition, and insulin resistance in HIV fat redistribution syndrome.

Authors:  Paula Freitas; Davide Carvalho; Ana Cristina Santos; António José Madureira; Esteban Martinez; Jorge Pereira; António Sarmento; José Luís Medina
Journal:  BMC Infect Dis       Date:  2014-06-23       Impact factor: 3.090

4.  Prevalence of testosterone deficiency in HIV-infected men under antiretroviral therapy.

Authors:  Ana Rita Gomes; Pedro Souteiro; Carolina Germana Silva; Bernardo Sousa-Pinto; Francisco Almeida; António Sarmento; Davide Carvalho; Paula Freitas
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

5.  Visceral adipose tissue and carotid intima-media thickness in HIV-infected patients undergoing cART: a prospective cohort study.

Authors:  Maria Teresa Beires; André Silva-Pinto; Ana Cristina Santos; António José Madureira; Jorge Pereira; Davide Carvalho; António Sarmento; Paula Freitas
Journal:  BMC Infect Dis       Date:  2018-01-11       Impact factor: 3.090

6.  Diabetes mellitus in HIV-infected patients: fasting glucose, A1c, or oral glucose tolerance test - which method to choose for the diagnosis?

Authors:  Ana Rita Coelho; Flávia Andreia Moreira; Ana Cristina Santos; André Silva-Pinto; António Sarmento; Davide Carvalho; Paula Freitas
Journal:  BMC Infect Dis       Date:  2018-07-06       Impact factor: 3.090

7.  Central/Peripheral fat mass ratio is associated with increased risk of hypertension in HIV-infected patients.

Authors:  Paula Freitas; Davide Carvalho; Ana Cristina Santos; António José Madureira; Sandra Xerinda; Esteban Martinez; Jorge Pereira; António Sarmento; José Luís Medina
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-06-13       Impact factor: 3.738

8.  Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistance.

Authors:  Paula Freitas; Davide Carvalho; Ana Cristina Santos; Joana Mesquita; Maria João Matos; Antonio Jose Madureira; Esteban Martinez; António Sarmento; José Luís Medina
Journal:  BMC Infect Dis       Date:  2012-08-06       Impact factor: 3.090

9.  Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV-positive patients but not to diagnose HIV-associated lipoatrophy: a pilot study.

Authors:  Patricia Pérez-Matute; Laura Pérez-Martínez; José R Blanco; Valvanera Ibarra; Luis Metola; Mercedes Sanz; Luis Hernando; Sagrario Martínez; Arsenio Ramírez; Enrique Ramalle-Gomara; José A Oteo
Journal:  J Int AIDS Soc       Date:  2013-12-27       Impact factor: 5.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.